Haridwar Today

Advanced Melanoma Pipeline Outlook Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals, Drugs and Companies

 Breaking News
  • No posts were found

Advanced Melanoma Pipeline Outlook Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals, Drugs and Companies

June 17
19:05 2024
Advanced Melanoma Pipeline Outlook Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals, Drugs and Companies

DelveInsight’s, “Advanced Melanoma Pipeline Insight 2024” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Advanced Melanoma pipeline landscape. It covers the Advanced Melanoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Melanoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Advanced Melanoma research. Learn more about our innovative pipeline today! @ Advanced Melanoma Pipeline Outlook

 

Key Takeaways from the Advanced Melanoma Pipeline Report

  • June 2024:- Immunocore Ltd– A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301. This is a phase 3, randomized, controlled study of IMC-F106C plus nivolumab compared to standard nivolumab regimens in HLA-A*02:01-positive participants with previously untreated advanced melanoma.
  • June 2024;- Yousef Zakharia– Cabozantinib and Pembrolizumab as a Front-line Therapy for Advanced Metastatic Melanoma. The study aims to evaluate the safety and preliminary efficacy of the combination of cabozantinib and pembrolizumab in advanced melanoma.
  • June 2024:-Diwakar Davar– In this is a randomized phase II study the addition of R-FMT to pembrolizumab /lenvatinib in PD-1 R/R melanoma will be evaluated over a 104-week period in patients with anti-PD-1 R/R disease. Patients with PD-1 refractory advanced melanoma are eligible to enroll, excluding patients with prior lenvatinib (or other TKI) exposure. Intestinal microbiome composition mediates response to anti-PD-1 by affecting systemic inflammatory tone.
  • June 2024:- Pfizer- The purpose of this study is to learn about the effects of 3 study medicines (encorafenib, binimetinib, pembrolizumab) compared to 2 study medicines (ipilimumab and nivolumab) given for the treatment of melanoma. The purpose of the study is to compare the efficacy of a triplet therapy (encorafenib, binimetinib, pembrolizumab) versus a doublet/control therapy (nivolumab and ipilimumab).
  • June 2024:- Regeneron Pharmaceuticals– A Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma. This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called REGN2810, also known as cemiplimab (each individually called a “study drug” or called “study drugs” when combined).
  • DelveInsight’s Advanced Melanoma pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Advanced Melanoma treatment.
  • The leading Advanced Melanoma Companies such as OncoSec Medical, Immunocore, Sanofi, TILT Biotherapeutics, Novartis Pharmaceuticals, Sumitomo Pharma, BioMed Valley Discoveries, Replimune, ImaginAb, Shanghai Pharmaceuticals, Seagen, Karyopharm Therapeutics, Hoffmann-La Roche, and others.
  • Promising Advanced Melanoma Therapies such as Tebentafusp, T3011, IMC-F106C, Relatlimab, HLX208, DCB-BO1301, Pembrolizumab, and others.

 

Stay informed about the cutting-edge advancements in Advanced Melanoma treatments. Download for updates and be a part of the revolution in cancer care @ Advanced Melanoma Clinical Trials Assessment

 

Advanced Melanoma Emerging Drugs Profile

  • Tebentafusp: Immunocore

Tebentafusp is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. Tebentafusp specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma, and is the first molecule developed using Immunocore’s ImmTAC technology platform designed to redirect and activate T cells to recognize and kill tumor cells. Tebentafusp has been granted Priority Review; Real Time Oncology Review; Breakthrough Therapy designation; Fast Track designation; and orphan drug designation by the FDA in the United States; orphan drug status in the European Union; and Promising Innovative Medicine (PIM) designation under the UK Early Access to Medicines Scheme for metastatic uveal melanoma. The drug is currently being evaluated under Phase II/III clinical trial for the treatment of Advanced Melanoma.

  • TAVO: OncoSec Medical

TAVO is DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. TAVO is administered directly into the tumor using OncoSec’s proprietary EP gene delivery system, which employs a series of momentary energy pulses. Those pulses are designed to increase the permeability of the cell membrane and facilitate uptake of IL-12 coded DNA into the tumor cells. The drug is currently being evaluated under Phase II clinical trials for the treatment of Advanced Melanoma.

 

Learn more about Advanced Melanoma Drugs opportunities in our groundbreaking metastatic prostate cancer research and development projects @ Advanced Melanoma Unmet Needs

 

Advanced Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

 

Advanced Melanoma Products have been categorized under various Molecule types such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

 

Discover the latest advancements in Advanced Melanoma treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Advanced Melanoma Market Drivers and Barriers, and Future Perspectives

 

Scope of the Advanced Melanoma Pipeline Report

  • Coverage- Global
  • Advanced Melanoma Companies- OncoSec Medical, Immunocore, Sanofi, TILT Biotherapeutics, Novartis Pharmaceuticals, Sumitomo Pharma, BioMed Valley Discoveries, Replimune, ImaginAb, Shanghai Pharmaceuticals, Seagen, Karyopharm Therapeutics, Hoffmann-La Roche, and others.
  • Advanced Melanoma Therapies- Tebentafusp, T3011, IMC-F106C, Relatlimab, HLX208, DCB-BO1301, Pembrolizumab, and others.
  • Advanced Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Advanced Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Advanced Melanoma Pipeline on our website @ Advanced Melanoma Emerging Drugs and Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Advanced Melanoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Advanced Melanoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name: Company name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. TAVO: OncoSec Medical
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug Name: Company Name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Advanced Melanoma Key Companies
  21. Advanced Melanoma Key Products
  22. Advanced Melanoma- Unmet Needs
  23. Advanced Melanoma- Market Drivers and Barriers
  24. Advanced Melanoma- Future Perspectives and Conclusion
  25. Advanced Melanoma Analyst Views
  26. Advanced Melanoma Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/